Peptide services/genscript/kenichi hanada
Ended Awarded
- Contract number
- HHSN26100033
- Awardee
-
Genscript USA Inc. UEI KVLBRRAQ6UX1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,418
Award facts
- Opportunity
-
- N02RC5256683 Solicitation number
- Detection of mutation-reactive T cells in patients with metastatic cancers Award Notice · Posted Apr 14, 2015
- Contract value 100% obligated
- $3,418.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Piscataway, NJ 08854, USA
Award details come from SAM.gov/FPDS.
About this award
This is a firm fixed-price delivery order awarded by the National Cancer Institute (NCI), an agency within the Department of Health and Human Services (HHS), to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The $3,418.30 contract is for the provision of peptide services, including gene synthesis, protein production, and antibody development, to support biomedical research and public health initiatives. While the contract does not have a set-aside designation, Genscript has received awards from other HHS components, such as the National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC), as well as the U.S. Department of Agriculture (USDA), including a $1.5 million blanket purchase agreement with USDA's Animal and Plant Health Inspection Service (APHIS) for SARS-CoV-2 surrogate virus neutralization test kits. Genscript's federal contracts have facilitated the company's involvement in various research and development efforts, including the rapid response to emerging infectious disease threats like COVID-19, influenza, HIV, and Ebola.
Quick answers
Who was awarded contract HHSN26100033?
HHSN26100033 was awarded to Genscript USA Inc. by National Cancer Institute (National Institutes of Health) on September 4, 2015.
How much is contract HHSN26100033 worth?
The government has obligated $3,418 on HHSN26100033.
Is contract HHSN26100033 an order under another contract?
Yes. HHSN26100033 is a delivery order under HHSN261201500015I, an indefinite delivery contract.
Was contract HHSN26100033 competed?
The extent of competition for HHSN26100033 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award